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Neonates	 experience	 adverse	 drug	 reactions	 (ADRs),	 but	 under-reporting	 of	 suspected	 ADRs	 to	
national	 spontaneous	 reporting	 schemes	 in	 this	 population	 is	 particularly	 high.	 A	 prospective	
observational	 study	 collected	 suspected	 neonatal	 ADRs	 at	 a	 tertiary	 neonatal	 unit.	 Cases	 were	
analysed	for	causality	by	six	assessors	using	three	existing	methods.	Sixty-three	suspected	ADR	cases	
were	identified	in	35/193	neonates	(18.1%).	The	proportion	of	suspected	ADRs	where	the	drug	was	
prescribed	 ‘off-label’	 was	 30/68	 (44.1%).	 When	 34	 cases	 were	 assessed	 for	 causality	 using	 three	
methods,	global	kappa	scores	of	less	than	0.3	for	each	tool	suggested	only	‘fair’	inter-rater	reliability.	
Neonatal	ADRs	can	be	captured	and	occur	from	a	variety	of	drugs	affecting	many	organ	systems.	The	












What is already known about this subject: 
• Neonates	 experience	 adverse	 drug	 reactions	 (ADRs),	 but	 there	 has	 been	 little	 prospective	
evaluation	of	the	drugs	suspected,	or	the	causality		
• Relatively	 few	 spontaneous	 reports	 of	 suspected	 ADRs	 relate	 to	 neonates,	 hindering	
pharmacovigilance	in	this	population		
• Several	 methods	 are	 currently	 available	 for	 assessing	 causality	 of	 suspected	 ADRs	 in	
neonates,	but	comparative	data	are	limited	
	



















doses	 normally	 used	 in	 man’	 [2].	 Recent	 studies	 into	 adverse	 drug	 reactions	 in	 children	 have	
indicated	a	 considerable	health	 risk	 for	 this	population,	with	 incidence	 rates	 ranging	 from	0.4%	 to	
10.3%	 for	paediatric	hospital	 admissions	 related	 to	ADRs	and	0.6%	 to	16.8%	 for	 the	proportion	of	
children	experiencing	an	ADR	during	their	admission	[3].		
Neonates	are	subject	to	different	adverse	drug	reaction	profiles	in	comparison	to	older	children	and	
adults	 [4,5].	The	development	of	a	child	 from	conception	 to	adulthood	 is	dynamic,	and	changes	 in	
organ	function	and	body	composition	affect	pharmacodynamics	and	pharmacokinetics	[6].	Neonates	
born	 preterm	 are	 subject	 to	 further	 variation	 in	 drug	 absorption,	 distribution,	 metabolism	 and	




rates	 to	 spontaneous	 reporting	 schemes	 for	 children	 are	 low	and	neonates	 are	particularly	 poorly	
represented	[9,10].	However,	the	historical	lack	of	inclusion	of	neonates	in	drug	trials	means	that	it	is	
particularly	important	to	generate	pharmacovigilance	data	in	this	population	[5].		
Evaluation	 of	 ADR	 reports	 is	 also	 very	 important.	 Evaluating	 the	 severity	 of	 an	 ADR	 assesses	 the	
importance	of	an	ADR	in	a	clinical	context,	and	a	neonatal	adverse	event	severity	scale	has	recently	
been	 developed	 through	 a	 Delphi	 consensus	 approach[11].	 Causality	 assessment	 tools	 enable	
structured	 assessment	 of	 the	 likelihood	 of	 drug-reaction	 accountability	 and	 could	 help	 to	 reduce	
disagreements	between	clinicians,	thus	increasing	ADR	reporting.	Such	tools	are	used	by	regulatory	
agencies	for	the	evaluation	of	ADR	reports	[12].		
The	Naranjo	 algorithm	 is	 a	widely	 used	 causality	 assessment	method	 [13].	However,	 a	 large-scale	
observational	study	into	ADRs	in	children	concluded	that	the	Naranjo	algorithm	was	not	suitable	to	
assess	 paediatric	 ADRs	 [12].	 Consequently,	 a	 new	 tool	 was	 developed	 for	 children	 and	 showed	
greater	inter-rater	reliability	[12].	The	resulting	‘Liverpool	ADR	Causality	Assessment	Tool’	(LCAT)	has	
not	 been	 assessed	 in	 neonates.	 A	 neonatal	modification	 of	 the	Naranjo	 algorithm	was	 developed	














Study design and participants 
A	 prospective	 observational	 study,	 the	 Adverse	 Drug	 Reactions	 in	 Neonates	 (ADRIN)	 study,	 was	
undertaken	at	a	tertiary	neonatal	centre	in	the	UK.		All	neonatal	inpatients	were	monitored	daily	for	
nine	 weeks.	 Neonates	 were	 reviewed	 daily	 up	 to	 28	 days	 post-term	 (corrected	 gestational	 age).	
Suspected	neonatal	ADR	cases	were	identified	by	medical	or	nursing	teams	or	by	the	researcher,	a	
5th	 year	 medical	 student.	 The	 review	 process	 is	 outlined	 in	 the	 daily	 structured	 clinical	 review	
guidance	found	in	appendix	2.	All	suspected	ADRs	were	discussed	and	approved	for	inclusion	by	the	
principal	investigator,	a	consultant	neonatologist.		
ADR case causality assessment 
Figure	1	outlines	case	selection	for	causality	assessment.	ADRs	caused	by	drugs	used	by	parents	(i.e.	
by	mother	in	labour)	were	excluded	as	the	causality	assessment	tools	used	have	not	been	validated	
for	 assessing	 this	 subtype	 of	 ADR.	 Six	 assessors	 (Table	 S1)	 were	 asked	 to	 complete	 three	 known	
causality	assessment	assessments	 for	each	case;	 the	Karch	and	Lasagna	method,	 the	New	Adverse	
Drug	Reactions	algorithm	for	 Infants	 in	the	Neonatal	 Intensive	Care	Unit	 (referred	to	within	as	the	
Du	Lehr	method)	and	the	Liverpool	ADR	Causality	Assessment	Tool	[12,	14,	15].	
Statistical analysis of ADR reports 
Neonatal	ADR	data	was	summarised	(Tables	S2-6).	All	suspected	ADR	cases	were	included	in	the	ADR	
case	analysis.		
Statistical analysis of causality assessments  
Inter-rater reliability: 
Inter-rater	 reliability	 was	 calculated	 using	 non-weighted,	 weighted	 and	 global	 kappa	 scores.	
















three	 reports	 detailing	 suspected	 ADRs	were	 recorded	 during	 the	 data	 collection	 period.	 Fifty-six	
reports	were	ascribed	to	drugs	prescribed	for	the	neonate,	and	seven	from	maternal	drugs.		
Neonatal characteristics 
The	 gestational	 ages	 of	 the	 neonates	 at	 birth	 ranged	 from	 23	 +	 6	 weeks	 to	 40	 +	 4	 weeks.	 The	
neonates’	corrected	gestational	ages	at	time	of	experiencing	an	ADR	ranged	from	26	+	1	weeks	to	40	
+	5	weeks	 (median	33	+	4	weeks).	The	birth	weights	of	 the	neonates	 ranged	 from	570g	 to	3990g,	
with	a	mean	birth	weight	of	1874g.	The	neonates’	working	weights	at	time	of	ADR	reporting	ranged	
from	580g	to	3990g	(mean	1390g).			
Adverse Drug Reactions Identified 
Thirty	five	of	the	193	neonates	reviewed	(18.1%)	were	suspected	to	have	experienced	one	or	more	
ADRs.	Of	 these	 neonates,	 28	 (80%)	were	 affected	 by	 drugs	 prescribed	 to	 the	 neonate,	 and	 seven	




only	 one	 suspected	 medication,	 18	 reports	 listed	 two	 medications,	 while	 two	 reports	 contained	
three	 suspected	medications.	Overall	 31	 different	 drugs	were	 suspected	 to	 have	 caused	 neonatal	
ADRs.	
The	 most	 commonly	 reported	 suspected	 ADRs	 were	 pyrexia	 (n=4),	 tachycardia	 (4),	
thrombocytopenia	 (3),	 altered	 consciousness	 (3)	 and	 renal	 failure	 (3).	 A	 complete	 list	 of	 the	
suspected	 ADRs	 identified	 is	 shown	 in	 table	 S3.	 The	 most	 common	 drug	 groups	 (by	 ATC	
classification)	 causing	ADRs	 (not	 including	 those	ADRs	suspected	 to	be	 from	maternal	drugs)	were	
those	drugs	in	the	cardiovascular	system	group	(28),	the	anti-infectives	for	systemic	use	group	(22)	
and	 the	 nervous	 system	 group	 (9)	 (table	 S4).	 Thirty	 ADR	 reports	 contained	medications	 that	 had	
been	prescribed	to	the	neonate	off-label	(table	S5).			
Seven	 reports	 were	 from	 medications	 administered	 to	 the	 mother,	 either	 during	 pregnancy	 or	
labour,	 identifying	seven	suspected	ADRs.	The	reports	detailed	a	 total	of	11	suspected	drugs,	nine	












S8-10).	Weighted	 kappa	 scores	 ranged	 from	 0.148	 to	 0.454	 for	 the	 Karch	 and	 Lasagna	 algorithm,	
0.114	to	0.483	for	the	Du	Lehr	and	0.121	to	0.428	for	the	LCAT.	Most	weighted	kappa	scores	for	each	









Kappa	 scores	 were	 also	 calculated	 to	 measure	 inter-tool	 reliability,	 the	 agreement	 when	 each	








In	 this	 study	 ADRs	were	 suspected	 to	 have	 affected	 term	 and	 preterm	 neonates,	 involving	many	
different	drugs.	It	can	be	challenging	to	distinguish	between	ADRs	and	Adverse	Events	(AEs),	and	this	
study	 demonstrates	 opinion	 contributes	 to	 categorisation	 of	 causality.	 An	 effective	 causality	
assessment	 tool	would	help	 to	 translate	clinician	concern	 into	categorical	 likelihood,	aiding	clinical	
drug	therapy	risk-benefit	analysis	and	ADR	reporting,	ultimately	improving	neonatal	care.	





A	wide	 range	 of	 reaction	 types	were	 observed	 and	 there	was	 at	 least	 one	 ADR	 report	 for	 nearly	
every	 organ	 system.	While	 cardiovascular	 system	 drugs,	 anti-infectives	 for	 systemic	 use,	 nervous	
system	 drugs,	 and	 sensory	 organ	 drugs	 were	 the	 most	 commonly	 identified	 ATC	 categories,	 the	
limited	size	of	this	study	means	it	is	not	possible	to	determine	whether	this	is	because	they	are	the	
more	harmful,	or	more	commonly	prescribed,	or	both.	A	recent	quasi-systematic	review	outlined	the	
most	 commonly	 prescribed	 drugs	 in	NICUs	worldwide	 [18].	 It	 found	 nine	 of	 the	 top	 twenty	most	
cited	 drugs	 were	 also	 listed	 on	 the	 A-PINCH	 list,	 a	 list	 of	 medications	 that	 pose	 high	 risks	 if	
medication	 errors	 occur	 [19].	 The	 list	 includes	 anti-infectives,	 potassium	 and	 concentrated	
electrolytes,	insulin	and	narcotics	and	sedatives,	all	of	which	are	used	on	neonatal	units.	In	total	22	
of	the	78	reported	drugs	in	this	study	are	A-PINCH	listed	drugs	[18,19].		
In	 recent	 years,	 it	 has	 become	 apparent	 that	 many	 pre-existing	 ADR	 assessment	 tools	 are	
inappropriate	for	assessing	paediatric	ADRs.	The	results	of	evaluating	the	three	causality	assessment	
methods	 to	determine	 their	 appropriateness	 for	 assessing	neonatal	ADRs	 show	no	 clear	 optimum	
method.	The	highest	Kappa	scores	demonstrated	inter-rater	reliability	of	 less	than	50%,	suggesting	
even	the	best	performing	tool	could	not	yet	have	a	useful	clinical	implementation.		
The	 highest	 inter-tool	 reliability	was	 observed	 between	 the	 Karch	 and	 Lasagna	 algorithm	 and	 the	












Some	assessors	demonstrated	moderate	and	good	 intra-rater	 reliability,	however,	 their	 inter-rater	




This	 study	 demonstrates	 that	 neonatal	 ADRs	 can	 be	 captured,	 but	 that	 more	 work	 is	 needed	 to	
design	 reliable	 causality	 assessment	 tools.	 The	 improvement	 in	 inter-rater	 reliability	 seen	 when	
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